PGA-timolol combo effective for POAG

Article

A combination of prostaglandin analog (PGA) and timolol 0.1 & gel reduces both IOP and fluctuations in primary-angle glaucoma patients, states a recent paper in European Journal of Ophthalmology.

A combination of prostaglandin analog (PGA) and timolol 0.1 & gel reduces both IOP and fluctuations in primary-angle glaucoma patients, states a recent paper in European Journal of Ophthalmology.

Dr Carlo Nucci et al., Ophthalmology Unit, Department of Exp. Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, administered fixed combinations of PGA-timolol in 64 eyes of 32 patients. This included 17 patients receiving a latanoprost-timolol fixed combination, 9 patients receiving a travoprost-timolol fixed combination and six who were administered bimatoprost-timolol fixed combination. The primary endpoint was the comparison between efficacy of fixed and unfixed combinations in lowering IOP and short-term IOP fluctuations.

All unfixed treatment combinations induced an IOP reduction that was significantly higher than the corresponding fixed treatment combinations. IOP diurnal fluctuations significantly decreased after unfixed combinations were administered, as well as increasing the percentage of patients with daily IOP fluctuation of 2 mm or less.

PGA and timolol was the most effective POAG treatment when administered as an unfixed combination. Once saily timolol 0.1% gel is a valuable treatment option as it reduces both IOP and daily fluctuations.

To read the journal abstract please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.